Insider Buying: CSL (ASX:CSL) Insider Acquires A$36,979.91 in Stock

CSL Limited (ASX:CSL) insider Carolyn Hewson acquired 244 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was purchased at an average cost of A$151.56 per share, with a total value of A$36,979.91.

CSL Stock Performance

The stock has a market capitalization of $77.43 billion, a PE ratio of 28.02, a PEG ratio of 1.29 and a beta of 0.32. The company has a quick ratio of 1.68, a current ratio of 1.86 and a debt-to-equity ratio of 64.46.

CSL Dividend Announcement

The firm also recently disclosed a Interim dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Wednesday, April 8th will be issued a dividend of $1.837 per share. The ex-dividend date is Monday, March 9th. This represents a yield of 121.0%. CSL’s payout ratio is currently 50.38%.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.